---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-232433"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2021-08-02T23:59:59+00:00"
generated_at: "2026-06-30T00:04:02.902199+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics appoints Kristian Humer to board and audit committee

## Summary
- Effective July 30, 2021, Kristian Humer appointed as Class II director and audit committee member.
- Humer previously Managing Director at Citigroup, now CFO/CBO of Viridian Therapeutics Inc.
- Initial option grant of 16,667 shares vesting over 36 months; annual retainer of $35,000 plus $7,500 for audit committee.
- No family relationships or arrangements with other directors/officers; standard indemnification agreement.
- Eligible for additional annual option of 8,333 shares vesting over 12 months, starting at 2022 annual meeting.

## SEC filing metadata
- accession: 0001193125-21-232433
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2021-08-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312521232433/0001193125-21-232433-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312521232433/d207449d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-232433
- JSON: https://secwatch.observer/filing/0001193125-21-232433.json
- Plain text: https://secwatch.observer/filing/0001193125-21-232433.txt

## Key facts
- Executive change
  Kristian Humer was appointed as director at Sensei Biotherapeutics, Inc..
  - Action: appointed
  - Role: director
  source text: Effective July 30, 2021, the board of directors (the “Board”) of Sensei Biotherapeutics, Inc. (the “Company”) appointed Kristian Humer to serve as a director of the Company and as a member of the Company’s audit committee.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312521232433/0001193125-21-232433-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.